Recent studies found that the dysregulation of SUMOylation contributed to the initiation and development of cancer [14,15,16,17], and that most SUMO-related genes, including SUMO-2 and SUMO-activating enzyme subunit 1 (SAE1), were overexpressed in many types of tumor [16,17,18]. Here, SAE1 is linked to cancer.